Table 2. Input data of main parameters of the included studies.

Reference; country	HZ incidence per 10,000 person years (range)a	Proportion of PHN cases (range)a	Average PHN duration	Proportion of cases in each pain state	Utilities	Vaccine efficacy [base or (range)a]	Duration of protection (years) [base (range)]	Vaccination costs in €2006 (range)
Edmunds et al. (2000);34 England and Wales	(39.5–115.8)	(3.3–34.4%)b	1.4 y	Mild: 77% Severe: 23%	Mild: 0.73 Severe: 0.47 (HZ and PHN)	70% (10–90%)	(2.5-lifetime)	€131 (€65-131)
Hornberger et al. (2006)35; USA	(99.5–142.9)	5.1%c	8 mo	NA	HZ: 0.811 PHN: 0.594	HZ: (13.2–65.4%)d PHN: 43.1%d BOI: 1.4%d (HZ utilities)	(3–30)	€223 (€56-559)
Pellissier et al. (2007)36; USA	(69.4–109.4)	(12.0–32.2%)e	NA	NA	Mild: 0.77 Moderate: 0.68 Severe: 0.55	HZ: (27.1–69.8%) PHN: 66.5%	Lifetime (12-lifetime)	€142 (€84-211)
Rothberg et al. (2007)37; USA	(49–117)	(6.9–18.5%)e	4.2yf	NA	HZ: 0.0129 (age: 60–69y) or 0.0216 (age: ≥ 70y)g PHN: 0.67	HZ:10.3–72.1% BOI: 4–29%	10 (4–18)	€130 (€26-131)
Brisson et al. (2008);38 Canada	(38.3–95.9)	(11.9–32.2%)e	0.31–1.50 y	Mild/moderate: 77%	Mild/moderate: 87% Severe: 51%	HZ: (26–75%) PHN: 67%	Lifetime (12-lifetime)	€111 (€37-148)
Najafzadeh et al. (2009);39 Canada	(99.5–115.7)	(6.9–18.5%)e	1.8 y	NA	Mild: 0.69 Moderate: 0.58 Severe: 0.30	HZ: (13.2–65.4%)d PHN: (4.3–47%)d	Half-life: 15 (5–30)	€104 (€35-139)
Van Hoek et al. (2009);40 England and Wales	(70.6–121.6)	(9–52%)e	1013 d (Long-term CRP)	Moderate/severe: 21%	Mild: 91% Moderate: 71% Severe: 32%	HZ: 37–78% BOI: incorporated in QALY weights PHN: 0% (0–44%)	7.5 (3.6–100)	€94 (€15-160)
Annemans et al. (2010);41 Belgium	(40–182)	(10.3–28.9%)b	(8.3–10.9 mo)	HZ: 32–41 (mild), 18–23 (moderate), 14–19 (severe) PHN: 17–42 mild, 9–16 (moderate), 49–67 (severe)	Mild: 0.69 Moderate: 0.58 Severe: 0.25	HZ: 37.6–63.9% PHN: 65.7–66.8% BOI: 2.2–3.3 mo reduction of PHN length	Lifetime (12-lifetime)	€139 (€98-157)
Moore et al. (2010)42; UK	(33.4–72.9)	(10.3–28.9%)b	(10.3–12.9 mo)	HZ: 32–41 (mild), 18–23 (moderate), 14–19 (severe) PHN: 17–42 mild, 9–16 (moderate), 49–67 (severe)	Mild: 0.69 Moderate: 0.58 Severe: 0.25	HZ: 37.6–63.9% PHN: 66.7–66.8% BOI: 2.2–3.3 mo reduction of PHN length	Lifetime (12-lifetime)	€153 (€94-182)
Van Lier et al. (2010)43; The Netherlands	(50.9–116.9)	As Van Hoek et al.40	As Van Hoek et al.40	As Van Hoek et al.40	As Van Hoek et al.40	As Van Hoek et al.40	7.5 (3.6–100)	€80 (€53-85)
Szucs et al. (2011);44 Switzerland	(30.6–81.7)	(10.3–28.9%)b	(8.3–10.9 mo)	HZ: 32–41 (mild), 18–23 (moderate), 14–19 (severe) PHN: 17–42 mild, 9–16 (moderate), 49–67 (severe)	Mild: 0.69 Moderate: 0.58 Severe: 0.25	HZ: 37.6–63.9% PHN: 65.7–66.9% BOI: 2.2–3.3 mo reduction of PHN length	Lifetime (12-lifetime)	€171 (€137-186)
Bilcke et al. (2012);45 Belgium	(54.8–128.7)	NA	Combined with HZ into SOI episode	NA	QALY loss per HZ case: (0.12–0.52)a	HZ: 35–78% Age/model/time-dependent efficacy	Most favor.: 7; Least favor.: lifetime	€110 (€23-110)
Bresse et al. (2013);46 France	(81.4–112.0)	(11.4–14.3%)e	(8.3–10.9 mo)	HZ: 32–41 (mild), 18–23 (moderate), 14–19 (severe) PHN: 17–42 mild, 9–16 (moderate), 49–67 (severe)	Mild: 0.69 Moderate: 0.58 Severe: 0.25	HZ: (18–64%) PHN: (5–55%) BOI: 2.2–3.3 mo reduction of PHN length	10 (7.5–20)	€143 (€114-171)
De Boer et al. (2013)47; The Netherlands	(65.8–83.5)	(4.7–11.1%)e	(8.3–10.9 mo)	HZ: 32–41 (mild), 18–23 (moderate), 14–19 (severe) PHN: 17–42 mild, 9–16 (moderate), 49–67 (severe)	Mild: 0.69 Moderate: 0.58 Severe: 0.25	HZ: 41.2–69.4% PHN: 0–44.0% BOI: 0–28.9%	12 (3.1-lifetime)	€88 (€78-135)

BOI: Burden-of-illness, Can$: Canadian dollar, CHF: Swiss franc, HZ: Herpes zoster, NA: Not available, PHN: Postherpetic neuralgia, QALY: Quality-adjusted life year, SOI: Severity of illness; ^a Depending on age and sex (minimum and maximum values are given); ^b PHN proportions after 1 mo; ^c PHN proportion after 6 mo; ^d Calculated by the authors; ^e PHN proportions after 3 mo; ^f If duration PHN longer than 12 mo; ^g Total QALY loss per HZ episode